10. Oppfølging

Aziz, N. M. (2007). Cancer survivorship research: state of knowledge, challenges and opportunities. Acta oncologica (Stockholm, Sweden), 46(4), 417-32.

Borhan, A., Reeder, J. E., O'Connell, M. J., Wright, K. O., Wheeless, L. L., di Sant'Agnese, P. A., McNally, M. L., & Messing, E. M. (2003). Grade progression and regression in recurrent urothelial cancer. The Journal of urology, 169(6), 2106-9.

Cancer i urinblåsa, njurbäcken, urin-ledare och urinrör: nationellt vårdprogram (2015). (rev. utg.) Lund: Regionala cancercentrum i Samverkan. Hentet fra http://www.cancercentrum.se/globalassets/cancerdiagnoser/urinvagar/urinblase--och-urinrorscancer/vardprogram/natvp_cancer_urinvagar_25aug15.pdf

Choe, J., Braschi-Amirfarzan, M., Tirumani, S. H., Shinagare, A. B., Kim, K. W., Ramaiya, N. H., & Krajewski, K. M. (2017). Updates for the radiologist in non-muscle-invasive, muscle-invasive, and metastatic bladder cancer. Abdominal radiology (New York), 42(11), 2710-2724.

EAU (2022). EAU Guidelines. Edition presented at the EAU Annual Congress Amsterdam Arnhem: European Association of Urology.

Efstathiou, J. A., Bae, K., Shipley, W. U., Kaufman, D. S., Hagan, M. P., Heney, N. M., & Sandler, H. M. (2009). Late Pelvic Toxicity After Bladder-Sparing Therapy in Patients With Invasive Bladder Cancer: RTOG 89-03, 95-06, 97-06, 99-06. Journal of Clinical Oncology, 27(25), 4055-4061.

Fujii, Y., Kawakami, S., Koga, F., Nemoto, T., & Kihara, K. (2003). Long-term outcome of bladder papillary urothelial neoplasms of low malignant potential. BJU international, 92(6), 559-62.

Fung, C., Fossa, S. D., Milano, M. T., Oldenburg, J., & Travis, L. B. (2013). Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study. Journal of Clinical Oncology, 31(30), 3807-14.

Gofrit, O. N., Pode, D., Lazar, A., Katz, R., & Shapiro, A. (2006). Watchful waiting policy in recurrent Ta G1 bladder tumors. European urology, 49(2), 303-6; discussion 306-7.

Gogna, N. K., Matthews, J. H., Turner, S. L., Mameghan, H., Duchesne, G. M., Spry, N., Berry, M. P., Keller, J., ... Trans Tasman Radiation Oncology, G. (2006). Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 81(1), 9-17.

Haugnes, H. S., Bosl, G. J., Boer, H., Gietema, J. A., Brydoy, M., Oldenburg, J., Dahl, A. A., Bremnes, R. M., & Fossa, S. D. (2012). Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. Journal of Clinical Oncology, 30(30), 3752-3763.

Herman, J. M., Smith, D. C., Montie, J., Hayman, J. A., Sullivan, M. A., Kent, E., Griffith, K. A., Esper, P., & Sandler, H. M. (2004). Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy. Urology, 64(1), 69-73.

Herr, H. W., Cookson, M. S., & Soloway, S. M. (1996). Upper tract tumors in patients with primary bladder cancer followed for 15 years. The Journal of urology, 156(4), 1286-7.

Holmang, S., Andius, P., Hedelin, H., Wester, K., Busch, C., & Johansson, S. L. (2001). Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. The Journal of urology, 165(4), 1124-8; discussion 1128-30.

Holmang, S., & Johansson, S. L. (2002). Stage Ta-T1 bladder cancer: The relationship between findings at first followup cystoscopy and subsequent recurrence and progression. The Journal of urology, 167(4), 1634-1637.

Hurle, R., Losa, A., Manzetti, A., & Lembo, A. (1999). Upper urinary tract tumors developing after treatment of superficial bladder cancer: 7-year follow-up of 591 consecutive patients. Urology, 53(6), 1144-1148.

Ito, A., Shintaku, I., Satoh, M., Ioritani, N., Aizawa, M., Tochigi, T., Kawamura, S., Aoki, H., ... Arai, Y. (2013). Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial. Journal of Clinical Oncology, 31(11), 1422-7.

Lagrange, J. L., Bascoul-Mollevi, C., Geoffrois, L., Beckendorf, V., Ferrero, J. M., Joly, F., Allouache, N., Bachaud, J. M., ... Study Group on Genito-Urinary, T. (2011). Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (GETUG 97-015). International journal of radiation oncology, biology, physics, 79(1), 172-8.

Leblanc, B., Duclos, A. J., Benard, F., Cote, J., Valiquette, L., Paquin, J. M., Mauffette, F., Faucher, R., & Perreault, J. P. (1999). Long-term followup of initial Ta grade 1 transitional cell carcinoma of the bladder. The Journal of urology, 162(6), 1946-50.

Majewski, W., & Tarnawski, R. (2009). Acute and late toxicity in radical radiotherapy for bladder cancer. Clinical oncology, 21(8), 598-609.

Mangar, S. A., Foo, K., Norman, A., Khoo, V., Shahidi, M., Dearnaley, D. P., Horwich, A., & Huddart, R. A. (2006). Evaluating the effect of reducing the high-dose volume on the toxicity of radiotherapy in the treatment of bladder cancer. Clinical oncology, 18(6), 466-73.

Mariappan, P., & Smith, G. (2005). A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database. The Journal of urology, 173(4), 1108-1111.

O'Brien, T., Ray, E., Singh, R., Coker, B., & Beard, R. (2011). Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). European urology, 60(4), 703-10.

Oge, O., Erdem, E., Atsu, N., ahin, A., & Ozen, H. (2000). Proposal for changes in cystoscopic follow-up of patients with low-grade pTa bladder tumor. European urology, 37(3), 271-4.

Ploussard, G., Daneshmand, S., Efstathiou, J. A., Herr, H. W., James, N. D., Rodel, C. M., Shariat, S. F., Shipley, W. U., ... Kassouf, W. (2014). Critical Analysis of Bladder Sparing with Trimodal Therapy in Muscle-invasive Bladder Cancer: A Systematic Review. European urology, 66(1), 120-137.

Pruthi, R. S., Baldwin, N., Bhalani, V., & Wallen, E. M. (2008). Conservative management of low risk superficial bladder tumors. The Journal of urology, 179(1), 87-90; discussion 90.

Shipley, W. U., Kaufman, D. S., Zehr, E., Heney, N. M., Lane, S. C., Thakral, H. K., Althausen, A. F., & Zietman, A. L. (2002). Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology, 60(1), 62-7; discussion 67-8.

Soloway, M. S., Bruck, D. S., & Kim, S. S. (2003). Expectant management of small, recurrent, noninvasive papillary bladder tumors. The Journal of urology, 170(2 Pt 1), 438-41.

Solsona, E., Iborra, I., Dumont, R., Rubio-Briones, J., Casanova, J., & Almenar, S. (2000). The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. The Journal of urology, 164(3), 685-689.

Sylvester, R. J., van der Meijden, A. P., Oosterlinck, W., Witjes, J. A., Bouffioux, C., Denis, L., Newling, D. W., & Kurth, K. (2006). Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. European urology, 49(3), 466-5; discussion 475-7.

Søndergaard, J., Holmberg, M., Jakobsen, A. R., Agerbæk, M., Muren, L. P., & Høyer, M. (2014). A comparison of morbidity following conformal versus intensity-modulated radiotherapy for urinary bladder cancer. Acta oncologica (Stockholm, Sweden), 53(10), 1321-8.

Weiss, C., Engehausen, D. G., Krause, F. S., Papadopoulos, T., Dunst, J., Sauer, R., & Rodel, C. (2007). Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. International journal of radiation oncology, biology, physics, 68(4), 1072-80.

Zieger, K., Wolf, H., Olsen, P. R., & Hojgaard, K. (2000). Long-term follow-up of noninvasive bladder tumours (stage Ta): recurrence and progression. BJU international, 85(7), 824-8.